Herein, we aimed to present the results of a real-world study on postoperative adjuvant EGFR-TKI therapy in patients with EGFR-mutation positive NSCLC, with a focus on evaluating the overall survival (OS) and DFS, to address these questions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.